Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
D000818:Animals; D001221:Aspartate Carbamoyltransferase / Q000037:antagonists & inhibitors*; D001224:Aspartic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002223:Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) / Q000037:antagonists & inhibitors*; D002277:Carcinoma / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007555:Isoxazoles / Q000008:administration & dosage* / Q000627:therapeutic use*; D008025:Ligases / Q000037:antagonists & inhibitors*; D008175:Lung Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D010080:Oxazoles / Q000008:administration & dosage* / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives; D011743:Pyrimidines / Q000096:biosynthesis; D051381:Rats
D007555:Isoxazoles; D009943:Organophosphorus Compounds; D010080:Oxazoles; D011743:Pyrimidines; D001224:Aspartic Acid; C013195:sparfosic acid; D001221:Aspartate Carbamoyltransferase; D008025:Ligases; D002223:Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); D010746:Phosphonoacetic Acid; C006303:acivicin; D005998:Glycine